The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
|
4 min read